NASDAQ$ILMN
Illumina · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Illumina's Q4 2020 financial performance reflected record revenue and strong growth, driven by increased sequencing instrument orders and overall business recovery.
Illumina reported a record fourth quarter revenue of $953 million, a slight increase compared to the prior year period. GAAP net income was $257 million, or $1.75 per diluted share, while non-GAAP net income was $179 million, or $1.22 per diluted share. The company saw record orders, including sequencing instruments, and anticipates continued recovery from the pandemic in 2021.
- Illumina delivered record fourth quarter revenue, exceeding expectations.
- The company experienced record orders, including sequencing instrument orders.
- GAAP net income attributable to Illumina stockholders was $257 million, or $1.75 per diluted share.
- Illumina anticipates continued recovery from the pandemic in 2021.
Headline financials
Revenue & EPS history
Illumina · Revenue · Quarterly
$953M
Revenue by segment
Illumina · $147M total across 1 segment · Q1 2023
- Service and Other Revenue$147M+5.0%100.0%
Forward guidance
For fiscal year 2021, the company expects year-over-year revenue growth in the range of 17% to 20%, and expects GAAP earnings per diluted share of $4.76 to $5.01 and non-GAAP earnings per diluted share of $5.10 to $5.35. This guidance excludes the potential impact from the pending acquisition of GRAIL, which we expect to close in the second half of 2021.
Tailwinds
- Expects year-over-year revenue growth in the range of 17% to 20%.
- Expects GAAP earnings per diluted share of $4.76 to $5.01.
- Expects non-GAAP earnings per diluted share of $5.10 to $5.35.
- Expanded NextSeq 2000 flow cell offering with launch of the P3 Reagent Kit and started shipping the NextSeq 1000
- Announced TSO 500 partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to advance comprehensive genomic profiling
Headwinds
- Guidance excludes the potential impact from the pending acquisition of GRAIL.
- Impact to business from the COVID-19 pandemic
- Changes in the rate of growth in the markets served
- Volume, timing and mix of customer orders among products and services
- Ability to adjust operating expenses to align with revenue expectations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.8%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-0.7%
Avg return
30 days after
35%
22 / 63 earnings
Positive
+21.1%
Q3 2025
Best reaction
-19.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.3% | +12.5% | +28.5% | |
| Q4 2025 | -10.4% | -12.9% | -6.7% | |
| Q3 2025 | +21.1% | +23.7% | +32.8% | |
| Q1 2025 | -4.9% | -1.7% | +3.9% | |
| Q3 2024 | +3.5% | +0.9% | -4.8% | |
| Q2 2024 | +4.9% | +7.0% | +12.4% | |
| Q1 2024 | -5.4% | -9.5% | -16.4% | |
| Q4 2023 | -3.6% | -6.4% | -5.3% | |
| Q3 2023 | -11.1% | -11.9% | +2.0% | |
| Q2 2023 | -0.6% | -5.9% | -14.9% | |
| Q1 2023 | -7.9% | -10.3% | -15.5% | |
| Q4 2022 | -4.9% | -5.8% | -2.9% | |
| Q3 2022 | +6.3% | +3.3% | +3.7% | |
| Q2 2022 | -8.3% | -3.3% | -7.5% | |
| Q1 2022 | -19.1% | -28.6% | -24.3% | |
| Q4 2021 | -10.0% | -7.0% | -17.4% | |
| Q3 2021 | -2.7% | -5.8% | -17.2% | |
| Q2 2021 | -1.5% | +0.4% | -7.5% | |
| Q1 2021 | -3.6% | -6.6% | -2.8% | |
| Q4 2020 | +12.2% | +9.5% | -10.0% | |
| Q3 2020 | -5.5% | -4.2% | +2.4% | |
| Q2 2020 | -11.2% | -14.9% | -14.6% | |
| Q1 2020 | -3.6% | -2.3% | +14.4% | |
| Q4 2019 | -5.8% | +2.5% | -6.7% | |
| Q3 2019 | -7.0% | -3.5% | +1.0% | |
| Q2 2019 | -0.3% | -1.2% | -6.4% | |
| Q1 2019 | -0.2% | -0.8% | -0.7% | |
| Q4 2018 | -5.3% | -1.7% | +8.7% | |
| Q3 2018 | -8.7% | -7.0% | -2.3% | |
| Q2 2018 | +7.7% | +10.4% | +16.4% | |
| Q1 2018 | -6.0% | -0.6% | +10.2% | |
| Q4 2017 | -3.8% | -8.9% | -7.1% | |
| Q3 2017 | -3.2% | -0.7% | +1.8% | |
| Q2 2017 | +13.8% | +11.9% | +17.6% | |
| Q1 2017 | +2.4% | +2.6% | -3.6% | |
| Q4 2016 | +1.4% | +1.8% | +5.3% | |
| Q3 2016 | -0.4% | -1.1% | -6.2% | |
| Q2 2016 | +7.7% | +10.4% | +12.5% | |
| Q1 2016 | -0.7% | — | — | |
| Q4 2015 | -6.0% | — | — | |
| Q3 2015 | -5.0% | — | — | |
| Q2 2015 | -9.4% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | -1.9% | — | — | |
| Q3 2014 | +8.9% | — | — | |
| Q2 2014 | -2.6% | — | — | |
| Q1 2014 | +8.8% | — | — | |
| Q4 2013 | +4.6% | — | — | |
| Q3 2013 | +10.6% | — | — | |
| Q2 2013 | +9.1% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | -3.6% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | -2.7% | — | — | |
| Q1 2012 | -1.9% | — | — | |
| Q1 2011 | -3.5% | — | — | |
| Q4 2011 | -4.1% | — | — | |
| Q4 2008 | -4.1% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q2 2010 | +3.6% | — | — | |
| Q2 2011 | +3.6% | — | — | |
| Q4 2010 | +3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro